Generic of Maxalt-MLT® Launches

Released: 01/07/2013   By: Mike Partridge, RPh

On December 31, 2012, Mylan received final FDA approval for and commenced shipping the generic equivalent for Merck’s branded product, Maxalt-MLT® (rizatriptan benzoate) orally disintegrating tablets. Maxalt-MLT® had estimated total U.S. annual sales of approximately $270 million.

Maxalt-MLT is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.